Covid-19 Ivermectin

Ytbnd

Guru
2. mar 2010
16.149
5.570
113
Evropsko potrdilo velja (170 = 180-10 dni), avgusta bo z njim lahko samo gledal Pag po internet kameri.
 

mosseero

fizik´alc
3. sep 2007
19.220
9.457
113
kod Džej-Zija
Saj ne, da je to že AndY nalepil čisto malo višje.

Me pa nekaj zanima. AndY in YTbmk nabijata na polno BigPharma gor, pa BigPharma malo dol itd. A zdaj, ko japonska BigPharma trdi, da iverca kaže nekaj učinika, je pa po novem BigPharma ok? Ali kako je zdaj s tem?
 
  • Všeč mi je
Reactions: sad
I

Izbrisan uporabnik 474

V bistvu se članka razlikujeta v eni zelo pomembni lastnosti - v prvem članku piše, da je Kowa skupaj z univerzo izvajala klinične preizkuse (v fazi 3). Drugi članek popravlja trditev prvega in sicer da gre za non-clinical trials.
 
  • Všeč mi je
Reactions: jest5

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113
Fact checkerji so fact checkali fact checkerje.

Jih je ze en bo buci usekal in jim povedal, kdo jih placuje. Namig, ena oseba sedi v upravi obeh podjetij Reuters in Pfizer.
 
  • Haha
Reactions: Ytbnd

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113
  • Všeč mi je
Reactions: jendomen

Ytbnd

Guru
2. mar 2010
16.149
5.570
113
Fact checkerji so fact checkali fact checkerje.

Jih je ze en bo buci usekal in jim povedal, kdo jih placuje. Namig, ena oseba sedi v upravi obeh podjetij Reuters in Pfizer.
Ko je v ZDA eden tožil FB fact checkerje na sodišču, se je izkazalo, da je njihova ugotovitev samo mnenje in ne ugotovitev stroke za posamezno področje.

Facebook Admits in Court Their “Fact-Checking” Is Just Opinion
 
19. jul 2007
2.756
1.479
113
Včasih so mi takšni zapisi dvignili pritisk, sedaj se mi pa samo še iskreno smili.
Za Andraža Terška bo pa res štetje pred korono in po koroni. In čisto nič ne bo isto.

Tudi uporabljeno besedišče je čedalje bolj ubogo.

Slovenistanski kre… geniji pa mislijo, da deluje le prvo!
Torej moramo učiti, pojasnjevati in objavljati ŠE MEDICINO?!
Pa kaj je to?! Pa kje mi sploh živimo?!

Če bi imel minimalno razumevanje, bi si vsaj minimalno predstavljal kako daleč narazen je in vitro delovanje (kar je opisano v citiranem članku) in terapevtska uporaba pri človeku.

Še za časa Trumpa so veliko preizkušali azitromicin (je AndY1 promptno obveščal), pa niso uspeli pokazati prav nobenega terapevtskegs efekta.
 

darjan

Vulkanizer
13. sep 2007
51.113
6.482
113
Meni tudi deluje bogo ta tersek, skoda ga je ker je edini tako na veliko udrihal proti ukrepom, drugi pa se skrivali zaradi lastne koristi…

ze ce bi poguglal ta atb bi nasel kovid studijo, ki kaze o efektu
 
  • Všeč mi je
Reactions: jendomen

mosseero

fizik´alc
3. sep 2007
19.220
9.457
113
kod Džej-Zija
Kolikokrat boste še to staro sranje lepili sem gor? Predebatirano že v nedogled. Svojemu pravničku pa sporoči, naj se raje prava drži, ker epidemija mu ne gre.
 

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113
Dr. Tess Lawrie's peer-reviewed meta-analysis was given an Altimetric score of 26,697, making it number eight out of some 18 million publications.


Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines​

 

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113

Na Fluvoxamine pa so naši pokvarjenci kar pozabili. Čudežno:

The Lancet:

Findings​

The study team screened 9803 potential participants for this trial. The trial was initiated on June 2, 2020, with the current protocol reporting randomisation to fluvoxamine from Jan 20 to Aug 5, 2021, when the trial arms were stopped for superiority. 741 patients were allocated to fluvoxamine and 756 to placebo. The average age of participants was 50 years (range 18–102 years); 58% were female. The proportion of patients observed in a COVID-19 emergency setting for more than 6 h or transferred to a teritary hospital due to COVID-19 was lower for the fluvoxamine group compared with placebo (79 [11%] of 741 vs 119 [16%] of 756); relative risk [RR] 0·68; 95% Bayesian credible interval [95% BCI]: 0·52–0·88), with a probability of superiority of 99·8% surpassing the prespecified superiority threshold of 97·6% (risk difference 5·0%). Of the composite primary outcome events, 87% were hospitalisations. Findings for the primary outcome were similar for the modified intention-to-treat analysis (RR 0·69, 95% BCI 0·53–0·90) and larger in the per-protocol analysis (RR 0·34, 95% BCI, 0·21–0·54). There were 17 deaths in the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR] 0·68, 95% CI: 0·36–1·27). There was one death in the fluvoxamine group and 12 in the placebo group for the per-protocol population (OR 0·09; 95% CI 0·01–0·47). We found no significant differences in number of treatment emergent adverse events among patients in the fluvoxamine and placebo groups.

Interpretation​

Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital.